Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Auxilium slips after reporting Xiaflex study data

By R&D Editors | July 30, 2012

Shares of Auxilium Pharmaceuticals Inc. slipped Monday after the company reported data from a new study of its drug Xiaflex.

Xiaflex is approved as a treatment for Dupuytren’s contracture, a condition that causes the tendons of the hand to thicken and shorten, making the fingers curve inward. The drug is approved for patients who have one “cord” of thickened tissue in their hands, and Auxilium is now testing the drug in patients who have more than one cord.

There were 60 patients in the study. Auxilium said about 60 percent of the patients’ joints experienced significant improvement after one injection of Xiaflex into each contracted joint. Auxilium said those rates were “numerically higher” than the results of patients who were treated with a placebo in other studies. The results couldn’t be evaluated for statistical significance because they came from separate clinical trials.

Shares of Auxilium lost 79 cents, or 3 percent, to $25.91 in afternoon trading.

The Malvern, Pa., company plans to start a larger trial in the third quarter. The Food and Drug Administration originally approved Xiaflex in early 2010. Auxilium is also planning to ask the FDA to approve the drug as a treatment for Peyronie’s disease, a condition in which scar tissue causes severe curvature of the penis, making sex difficult. It says it will file for that approval before the end of 2012.

In the trial, the most common side effects were bruising, pain and swelling at the injection site. Auxilium reported two other serious side effects. It said one patient was hospitalized for 24 hours for pain after two injections into the patient’s little finger. Another patient suffered a middle finger ligament injury. Auxilium said both of those side effects have been observed in other studies.

Related Articles Read More >

Novel mass spectrometry solution simplifies insight gathering into macromolecular complexes
ENPICOM launches display solution to accelerate antibody selection while maximizing precision
Thermo Fisher Scientific autoimmune-testing instruments now available in the U.S.
Thermo Fisher Scientific and Qatar Genome Program partner to advance precision medicine 
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars